[Experimental rationale for the use of medapec as the drug of choice in treating echinococcosis].
The dosage form of medamine-medapec was found to have a high antiechinococcal activity in experiments on laboratory animals. Its efficacy was shown in treating larval alveolar echinococciasis in mice and cotton rats with different doses and courses as compared with medamine and albendazole. It was ascertained that for its high larvicidal activity, medapec should be given to animals regularly during a day. The daily dose of the drug should be gradually increased. In complying with these conditions, the duration of effective courses of therapy drastically reduces.
Dzhabarova
V I
VI
Kovalenko
F P
FP
Lebedeva
M N
MN
D000284:Administration, Oral; D000818:Animals; D000923:Anticestodal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D002219:Carbamates; D004195:Disease Models, Animal; D004337:Drug Carriers; D004353:Drug Evaluation, Preclinical; D004445:Echinococcosis, Pulmonary / Q000188:drug therapy* / Q000469:parasitology; D004446:Echinococcus; D005260:Female; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D010368:Pectins; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000469:parasitology; D051381:Rats; D016205:Sigmodontinae
D000923:Anticestodal Agents; D001562:Benzimidazoles; D002219:Carbamates; D004337:Drug Carriers; D010368:Pectins; C006698:carbendazim